{
    "id": 22275,
    "fullName": "SLC34A2 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "SLC34A2 positive indicates the presence of the SLC34A2 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 10568,
        "geneSymbol": "SLC34A2",
        "terms": [
            "SLC34A2",
            "NAPI-3B",
            "NAPI-IIb",
            "NPTIIb",
            "PULAM"
        ]
    },
    "variant": "positive",
    "createDate": "05/10/2016",
    "updateDate": "05/27/2016",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6210,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, XMT-1536 inhibited growth of SLC34A2-positive non-small cell lung cancer cells in culture (Proceedings of AACR, Vol 57, Apr 2016, Abstract # 1194).",
            "molecularProfile": {
                "id": 22842,
                "profileName": "SLC34A2 positive"
            },
            "therapy": {
                "id": 4094,
                "therapyName": "XMT-1536",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5466,
                    "pubMedId": null,
                    "title": "Discovery and preclinical development of a highly potent NaPi2b-targeted antibody-drug conjugate (ADC) with significant activity in patient-derived non-small cell lung cancer (NSCLC) xenograft models",
                    "url": "http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=43ef76fe-c845-4b4b-8531-601f2b1c2c32&cKey=132d0ba9-cd0a-4831-b61a-3bba3ae06518&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16225,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, treatment with DNIB0600A (lifastuzumab vedotin) compared to treatment with Doxil (pegylated liposomal doxorubicin) resulted in an improved progression-free survival (5.3 mo vs 3.1 mo) and objective response rate of 34% (16/47) vs 15% (7/48), respectively, in platinum-resistant ovarian cancer patients, in which the majority expressed Slc34a2 (PMID: 29401246; NCT01991210).",
            "molecularProfile": {
                "id": 22842,
                "profileName": "SLC34A2 positive"
            },
            "therapy": {
                "id": 1345,
                "therapyName": "DNIB0600A",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14352,
                    "pubMedId": 29401246,
                    "title": "Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29401246"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6209,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, XMT-1536 inhibited growth of a SLC34A2-positive human ovarian cancer cell line in culture and induced tumor regression in xenograft models (Proceedings of AACR, Vol 57, Apr 2016, Abstract # 1194).",
            "molecularProfile": {
                "id": 22842,
                "profileName": "SLC34A2 positive"
            },
            "therapy": {
                "id": 4094,
                "therapyName": "XMT-1536",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5466,
                    "pubMedId": null,
                    "title": "Discovery and preclinical development of a highly potent NaPi2b-targeted antibody-drug conjugate (ADC) with significant activity in patient-derived non-small cell lung cancer (NSCLC) xenograft models",
                    "url": "http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=43ef76fe-c845-4b4b-8531-601f2b1c2c32&cKey=132d0ba9-cd0a-4831-b61a-3bba3ae06518&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 22842,
            "profileName": "SLC34A2 positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}